Advanced search
Publication Cover
Acta Cardiologica Volume 74, 2019 - Issue 2
Submit an article Journal homepage
473
Views
18
CrossRef citations to date
0
Altmetric
Original Scientific Paper

Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome

Frederik H. VerbruggeDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0599-9290
ORCID Icon,
Pieter MartensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; ORCID Iconhttp://orcid.org/0000-0002-3070-221X
ORCID Icon,
Koen AmelootDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium;
,
Veerle HaemelsDepartment of Cardiovascular Medicine, UZ Leuven, Leuven, Belgium;
,
Joris PendersDepartment of Laboratory Medicine, Ziekenhuis Oost-Limburg, Genk, Belgium;
,
Matthias DupontDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium;
,
W. H. Wilson TangDepartment of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA
,
Walter DroognéDepartment of Cardiovascular Medicine, UZ Leuven, Leuven, Belgium;
&
Wilfried MullensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium;
show all
Pages 100-107 | Received 03 Feb 2018, Accepted 15 Mar 2018, Published online: 27 Mar 2018

References

  • Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
  • Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776–803.
  • Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161.
  • Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
  • Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. N Engl J Med. 2011;364:11–21.
  • Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10:297–303.
  • Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62:1585–1593.
  • Muzzarelli S, Maeder MT, Toggweiler S, et al. Frequency and predictors of hyperkalemia in patients >/=60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol. 2012;109:693–698.
  • Hensen J, Abraham WT, Durr JA, et al. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11:441–446.
  • van Vliet AA, Donker AJ, Nauta JJ, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71:21A–28A.
  • Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2:370–376.
  • Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5:54–62.
  • Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261–270.
  • Verbrugge FH, Dupont M, Bertrand PB, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70:265–273.
  • Verbrugge FH, Mullens W, Tang WH. Management of Cardio-Renal Syndrome and Diuretic Resistance. Curr Treat Options Cardio Med. 2016;18:11.
  • Butler J, Hernandez AF, Anstrom KJ, et al. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in. Heart Failure. JACC Heart Fail. 2016;4:726–735.
  • Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: the ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. 2017;2:950–958.
  • Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.
  • Hoss S, Elizur Y, Luria D, et al. Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure. Am J Cardiol. 2016;118:1868–1874.
  • Singh D, Shrestha K, Testani JM, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail. 2014;20:392–399.
  • Verbrugge FH, Nijst P, Dupont M, et al. Urinary composition during decongestive treatment in heart failure with reduced ejection fraction. Circ Heart Fail. 2014;7:766–772.
  • Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-31.
  • Verbrugge FH. Decongestion: more than meets the eye! Eur J Heart Fail. 2016;18:192–194.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.